Amylyx Pharmaceuticals (AMLX) Accounts Payables: 2021-2025
Historic Accounts Payables for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $5.3 million.
- Amylyx Pharmaceuticals' Accounts Payables rose 259.05% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 259.05%. This contributed to the annual value of $2.9 million for FY2024, which is 86.68% down from last year.
- As of Q3 2025, Amylyx Pharmaceuticals' Accounts Payables stood at $5.3 million, which was up 62.08% from $3.3 million recorded in Q2 2025.
- Over the past 5 years, Amylyx Pharmaceuticals' Accounts Payables peaked at $24.7 million during Q2 2023, and registered a low of $1.5 million during Q3 2024.
- In the last 3 years, Amylyx Pharmaceuticals' Accounts Payables had a median value of $5.3 million in 2025 and averaged $9.8 million.
- In the last 5 years, Amylyx Pharmaceuticals' Accounts Payables tumbled by 86.68% in 2024 and then skyrocketed by 259.05% in 2025.
- Over the past 5 years, Amylyx Pharmaceuticals' Accounts Payables (Quarterly) stood at $4.4 million in 2021, then surged by 43.12% to $6.3 million in 2022, then soared by 252.58% to $22.1 million in 2023, then slumped by 86.68% to $2.9 million in 2024, then skyrocketed by 259.05% to $5.3 million in 2025.
- Its last three reported values are $5.3 million in Q3 2025, $3.3 million for Q2 2025, and $4.8 million during Q1 2025.